Daniel J. Drucker, MD
ObesityWeek 2024 – Oral presentation
Key messages
- GLP-1RA have wider effects beyond simply inhibiting food intake.
- There is an established evidence base in T2D, DKD, CVD, and obesity.
- New data also show improvement in MASH.
- Agents in development include new dual and triple agonists, as well as combinations and oral options.
